A Phase Ib Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), and Post-Essential Thrombocythemia MF (post-ET MF)
The goal of this clinical research study is to find the highest tolerable dose of PU-H71 (dihydrochloride salt) that can be given in combination with Jakafi® (ruxolitinib) to patients with myelofibrosis (MF).
Treatment Location: N/A
IRB Review and Approval Date: 02/08/2018
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: